111 Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

111 Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.67M	Buy	3,740 +848	+29%	+$395K	0.41%	45
2025 Q4	$1.31M	Sell	2,892 -1,471	-34%	-$634K	0.29%	66
2025 Q3	$1.71M	Buy	+4,363	New	+$1.82M	0.32%	58
2025 Q1	–	Sell	-3,304	Closed	-$1.33M	–	634
2024 Q4	$1.33M	Buy	+3,304	New	+$1.53M	0.28%	70

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

111 Capital's VRTX Position: Q1 2026 in Review

111 Capital increased its Vertex Pharmaceuticals (VRTX) stake by 29% in Q1 2026, buying an estimated $395K and bringing the position to 3,740 shares worth $1.67M. The position accounts for 0.41% of the portfolio, ranked #45.

111 Capital first reported a position in VRTX in Q4 2024 and has held it in 4 quarters since. The position peaked at $1.71M in Q3 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

111 Capital held 3,740 shares of Vertex Pharmaceuticals worth $1.67M as of Q1 2026.
111 Capital bought 848 Vertex Pharmaceuticals shares in Q1 2026, an estimated $395K.
Vertex Pharmaceuticals made up 0.41% of 111 Capital's portfolio in Q1 2026, its #45 holding.
111 Capital first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 4 quarters since.
111 Capital's Vertex Pharmaceuticals position peaked at $1.71M in Q3 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on 111 Capital's 13F filing for Q1 2026, filed 11 May 2026.